LIFESTYLE MODIFICATIONS
Randomized controlled trials have shown that individuals at high risk for developing type 2 diabetes (IFG, IGT, or both) can significantly decrease the rate of diabetes onset with particular interventions (1) (2) (3) (4) (5) . These include intensive lifestyle modification programs that have been shown to be very effective (;58% reduction after 3 years). Follow-up of all three large studies of lifestyle intervention has shown sustained reduction in the rate of conversion to type 2 diabetes: 43% reduction at 20 years in the Da Qing study (6) , 43% reduction at 7 years in the Finnish Diabetes Prevention Study (DPS) (7) , and 34% reduction at 10 years in the U.S. Diabetes Prevention Program Outcomes Study (DPPOS) (8) . A cost-effectiveness model suggested that lifestyle interventions in the Diabetes Prevention Program (DPP) are cost-effective (9) . Actual cost data from the DPP and DPPOS confirm that the lifestyle interventions are highly cost-effective (10) . Group delivery of the DPP intervention in community settings has the potential to be significantly less expensive while still achieving similar weight loss (11) . The Centers for Disease Control and Prevention (CDC) helps coordinate the National Diabetes Prevention Program, a resource designed to bring evidencebased lifestyle change programs for preventing type 2 diabetes to communities (http://www.cdc.gov/diabetes/prevention/index.htm).
Given the clinical trial results and the known risks of progression of prediabetes to diabetes, people with an A1C 5.7-6.4%, IGT, or IFG should be counseled on lifestyle changes with goals similar to those of the DPP (7% weight loss and moderateintensity physical activity of at least 150 min/week).
PHARMACOLOGICAL INTERVENTIONS
Pharmacological agents, such as metformin, a-glucosidase inhibitors, orlistat, and thiazolidinediones, have each been shown to decrease incident diabetes to various degrees. Metformin has the strongest evidence base and demonstrated longterm safety as pharmacological therapy for diabetes prevention (12) . For other drugs, cost, side effects, and lack of a persistent effect require consideration.
Metformin was less effective than lifestyle modification in the DPP and DPPOS but may be cost-saving over a 10-year period (10) . It was as effective as lifestyle modification in participants with BMI $35 kg/m 2 but not significantly better than placebo in those over 60 years of age (1) . In the DPP, for women with a history of GDM, metformin and intensive lifestyle modification led to an equivalent 50% reduction in diabetes risk (13). Metformin may be recommended for very high-risk individuals (e.g., with history of GDM, who are very obese, and/or those with more severe or progressive hyperglycemia).
People with prediabetes often have other cardiovascular risk factors, such as obesity, hypertension, and dyslipidemia, and are at an increased risk for cardiovascular disease events. While treatment goals are the same as for other patients without diabetes, increased vigilance is warranted to identify and treat these and other risk factors (e.g., smoking).
DIABETES SELF-MANAGEMENT EDUCATION AND SUPPORT
The standards for DSME and DSMS (see Section 4. Foundations of Care) can also apply to the education and support of people with prediabetes. Currently, there are significant barriers to the provision of education and support to those with prediabetes. However, the strategies for supporting successful behavior change and the healthy behaviors recommended for people with prediabetes are largely identical to those for people with diabetes. Given their training and experience, providers of DSME and DSMS are particularly well equipped to assist people with prediabetes in developing and maintaining behaviors that can prevent or delay the onset of diabetes (14) (15) (16) .
